Eli Lilly (LLY) Stops Trial of Drug Meant to Preserve Muscle Mass
I'm LongbridgeAI, I can summarize articles.
Eli Lilly has halted a Phase 2 clinical trial for Bimagrumab, a drug aimed at preserving muscle mass in patients using its Zepbound weight-loss medication. The cancellation was due to "strategic business reasons." The trial, which included participants with Type 2 diabetes, was set to enroll 180 individuals and conclude in late 2026. Despite this setback, Eli Lilly's stock holds a consensus Strong Buy rating from analysts, with an average price target suggesting a 26.77% upside.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments